Convidecia (redirect from Ad5-nCoV) AD5-nCOV, trade-named Convidecia, is a single-dose viral vector vaccine for COVID-19 that is also used as an inhaled booster. It was developed by CanSino... 36 KB (3,379 words) - 00:52, 31 December 2023 |
Adenoviridae (redirect from Ad5) Recombinant adenovirus type-5 (Ad5) are being used by Ad5-nCoV, ImmunityBio and UQ-CSL V451. The Gam-COVID-Vac (aka Sputnik-V) product is innovative because... 49 KB (5,557 words) - 01:25, 8 March 2024 |
V by the Gamaleya Institute (February 2, 2021) Ad5-nCoV by CanSino Biologics Inc. (February 9, 2021) CoronaVac by Sinovac Research and Development Co... 10 KB (796 words) - 15:33, 1 January 2024 |
5AD (radio station), Adelaide, South Australia, Australia Ad5-nCoV, COVID-19 vaccine Ad5-EBOV, Ebola vaccine 5 (disambiguation) AD (disambiguation) This... 789 bytes (149 words) - 17:39, 2 October 2021 |
tozinameran and mRNA-1273, the DNA vaccine ZyCoV-D as well as the viral vectors AZD1222, Ad26.COV2.S, Ad5-nCoV, and Sputnik V. In addition, genetic vaccines are... 8 KB (1,186 words) - 19:47, 27 October 2022 |
trials for Chinese COVID-19 vaccine Ad5-Ncov: Ifax". Reuters. 7 December 2020. Retrieved 7 December 2020. Eltahir N (9 August 2020). "CanSino to start... 15 KB (1,075 words) - 05:06, 9 April 2024 |
Biological Sciences at the University of Montreal. Starting in June, the Ad5-nCoV vaccine, developed by the Chinese company CanSino Biologics (Tianjin, China)... 180 KB (17,227 words) - 15:36, 6 March 2024 |